阿帕替尼为主的方案多线治疗晚期妇科恶性肿瘤的临床观察

Clinical observation of apatinib based regimen of multiline treatment of advanced gynecological malignant tumors

目的:探讨阿帕替尼为主的方案治疗晚期妇科恶性肿瘤的疗效及安全性。方法:回顾性分析本院2016年1月至2017年8月接受阿帕替尼为主的方案治疗晚期妇科恶性肿瘤患者13例,分别采用RECIST 1.1版与NCI-CTC 4.0版标准评价近期疗效和不良反应。采用Kaplan-Meier法进行生存分析。结果:11例患者可评价疗效,无完全缓解(CR)病例,部分缓解(PR)3例,稳定(SD)6例和进展(PD)2例,总有效率(RR)和疾病控制率(DCR)分别为27.3%和81.8%。中位无进展生存率(PFS)6.0个月(95%CI:2.837～9.163个月),中位总生存率(OS)12.0个月(95%CI:5.674～18.326个月)。常见不良反应包括骨髓抑制、手足综合征、高血压、蛋白尿、出血。结论:阿帕替尼为主的方案对于多线治疗晚期妇科恶性肿瘤具有一定的疗效,且耐受性较好。

Objective： To investigate the efficacy and safety of apatinib based regimen in the treatment of advanced gynecological malignant tumors. Methods： A retrospective analysis of our hospital from January 2016 to August 2017,13 patients received apatinib based regimen in the treatment of advanced gynecological malignant tumor. Using RECIST（ version 1. 1） and NCI-CTC（ version 4. 0） to evaluate the efficacy and adverse events respectively. Kaplan-Meier was used for survival analysis. Results： 11 patients could evaluate the efficacy. There were no CR cases,3 PR cases,6 SD cases and 2 PD cases. RR and DCR were 27. 3% and 81. 8% respectively. The median PFS was 6 months（ 95% CI： 2. 837 ~ 9. 163 months） and the median OS was 12 months（ 95% CI： 5. 674 ~ 18. 326 months）. Common adverse events included myelosuppression,hand foot syndrome,hypertension,proteinuria,and bleeding. Conclusion：Apatinib based regimens have certain curative effect for multi line treatment of advanced gynecological malignant tumor,and are well tolerated.